Two new contract wins for biotech company
York-based biotech business, Aptamer Group, has signed two contracts with a top five pharma partner valued at up to £219,000.
Aptamer develops Optimer ® binders, which can be used as synthetic alternatives to antibodies.
Its first new contract is for the development of an Optimer pair to a neurodegenerative biomarker for use in an immunoassay platform.
The second is a follow-on contract for the final stage of Optimer development to a neuronal protein target for immunohistochemistry (IHC), following positive results in the earlier stages of Optimer development.
Dr Rob Quinn, CEO of Aptamer Group, said: “I am pleased to be able to extend our partnership with this top five pharma partner.
“These two projects are further evidence of the need for Optimer binders to meet challenging requirements for use in real-world applications when, to date, antibodies have been unable to provide a satisfactory solution, such as IHC.
“Building awareness and adoption of Optimer technology by such partners is key to allowing us to deliver on our strategy of executing therapeutic, diagnostic, and bioprocessing licensing deals.”
